Browsing: Ideas & Technologies

Ideas & Technologies
0
RXi Pharma developing the next generation of immuno-oncology therapeutics

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (sd-rxRNA®) therapeutic platform. The Company’s discovery and research efforts are focused on developing sd-rxRNA therapeutic compounds to be used with an Adoptive Cell Transfer (ACT) approach. This process uses immune…

Ideas & Technologies
0
TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells.

TargaGenix develops novel compounds that are effective on both drug-resistant tumors and cancer stem cells.  In numerous preclinical models of cancer, including colon, pancreatic, prostate, breast and lung cancers the company’s lead product SBT-1214 has shown to completely eliminate the tumor.  Additional studies have shown that SBT-1214 is able to…

Ideas & Technologies
0
OTraces uses math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer

OTraces has developed a disruptive technology using math/physics-based noise suppression techniques to enhance the accuracy and performance of cancer diagnostics. By using these techniques to access the active proteins found in the tumor microenvironment (TME) with, for the first time, simple and cost-effective blood based-tests, OTraces has solved the problem of…

Ideas & Technologies
0
Hookipa Biotech best-in-class active immunization therapies for infectious diseases and oncology

Hookipa Biotech AG is a clinical stage biotech company aiming to develop best-in-class active immunization therapies for infectious diseases and oncology.   The company’s proprietary TheraT® and Vaxwave® platforms have shown promising abilities to elicit high neutralizing antibody responses, but also necessary levels of T cell responses, currently missing in most…

Ideas & Technologies
0
CytRx Corporation Advancing Four New Linker-Activated Drug Release Candidates to IND-Enabling Studies

LADR™ Technology May Successfully Harness Potential of Known, Efficacious Anti-Cancer Compounds Whose Development Has Been Impeded CytRx Corporation (NASDAQ: CYTR), a Los Angeles-based biopharmaceutical research and development company specializing in oncology, recently selected four new investigational-stage Linker-Activated Drug Release (LADR™) candidates for advancement toward clinical testing in cancer patients.  At…

1 2 3 6